AI Article Synopsis
- Nitric oxide acts as a messenger molecule that helps widen blood vessels, particularly in the lungs, allowing better blood flow without affecting overall body circulation pressure.
- Inhaled nitric oxide (iNO) is recommended for use in full-term and late preterm infants to treat conditions like persistent pulmonary hypertension and hypoxic respiratory failure.
- Recent studies indicate an increasing off-label use of iNO for preterm infants under 34 weeks gestation, prompting a review of its effectiveness, safety, dosing, and combination with other drugs for better clinical outcomes.
Article Abstract
Nitric oxide is a messenger molecule for vasodilation of vascular smooth muscle cells, and inhaled nitric oxide (iNO) can dilate pulmonary blood vessels and reduce pulmonary vascular resistance, thereby reducing pulmonary artery pressure, but with no influence on systemic circulation pressure. Guidelines in China and overseas recommend the use of iNO in full-term infants and late preterm infants, and it has been proved that it has a marked effect on persistent pulmonary hypertension and hypoxic respiratory failure in such infants. However, recent studies have shown that there is an increase in the off-label use of iNO in preterm infants with a gestational age of <34 weeks. This article reviews the research progress on the efficacy, safety, timing, dose, and withdrawal mode of iNO and its combination with vasoactive drugs in the treatment of preterm infants with a gestational age of <34 weeks in China and overseas, so as to provide a reference for clinical application.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511234 | PMC |
| http://dx.doi.org/10.7499/j.issn.1008-8830.2303146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!